{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "the-program", "type": "clause", "offset": [6, 17]}, {"key": "article-iv", "type": "definition", "offset": [31, 41]}, {"key": "development-agreement", "type": "clause", "offset": [50, 71]}], "snippet": "means the program described in Article IV of this Development Agreement.", "size": 6, "samples": [{"hash": "dK18dtgUNbA", "uri": "/contracts/dK18dtgUNbA#clinical-development-program", "label": "Development Collaboration and License Agreement (Genentech Inc)", "score": 18.0, "published": true}, {"hash": "TY6mD2lMhe", "uri": "/contracts/TY6mD2lMhe#clinical-development-program", "label": "Development Collaboration and License Agreement (Cytotherapeutics Inc/De)", "score": 18.0, "published": true}, {"hash": "2PlV8Lh4mPy", "uri": "/contracts/2PlV8Lh4mPy#clinical-development-program", "label": "Development Collaboration and License Agreement (Cytotherapeutics Inc/De)", "score": 18.0, "published": true}], "hash": "e7f25ee63b0480899b3126bad46ecc34", "id": 1}, {"snippet_links": [{"key": "clinical-development-activities", "type": "clause", "offset": [10, 41]}, {"key": "by-merck", "type": "clause", "offset": [53, 61]}, {"key": "article-ii", "type": "definition", "offset": [78, 88]}], "snippet": "means the clinical development activities undertaken by MERCK as set forth in Article II herein", "size": 5, "samples": [{"hash": "a702SfsGpx9", "uri": "/contracts/a702SfsGpx9#clinical-development-program", "label": "Development and License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "QI3CkQsJe0", "uri": "/contracts/QI3CkQsJe0#clinical-development-program", "label": "Development and License Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "1iEJq0xlHJs", "uri": "https://ir.ionis.com/static-files/9a411f92-c822-45b5-ab66-33a6ae1b6427", "label": "ir.ionis.com", "score": 12.7373656825, "published": false}], "hash": "465f11cd95a0c012a2e971b0966e9c0b", "id": 2}, {"snippet_links": [{"key": "clinical-development-activities", "type": "clause", "offset": [10, 41]}, {"key": "each-party", "type": "definition", "offset": [79, 89]}, {"key": "pursuant-to-a", "type": "definition", "offset": [90, 103]}, {"key": "clinical-development-plan", "type": "definition", "offset": [104, 129]}], "snippet": "means the clinical development activities conducted by (or to be conducted by) each Party pursuant to a Clinical Development Plan.", "size": 5, "samples": [{"hash": "lxkjSiz3KL3", "uri": "/contracts/lxkjSiz3KL3#clinical-development-program", "label": "Sublicense Agreement (BTHC VI Inc)", "score": 21.0, "published": true}, {"hash": "d0XuHdeseKc", "uri": "/contracts/d0XuHdeseKc#clinical-development-program", "label": "Strategic Alliance Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}, {"hash": "8WQL5ppxoBO", "uri": "/contracts/8WQL5ppxoBO#clinical-development-program", "label": "Strategic Alliance Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}], "hash": "8757f5e16ac22b3bce012dfb56124300", "id": 3}, {"snippet_links": [{"key": "the-pre", "type": "clause", "offset": [6, 13]}, {"key": "clinical-studies", "type": "clause", "offset": [14, 30]}, {"key": "clinical-trials", "type": "definition", "offset": [32, 47]}, {"key": "regulatory-filings", "type": "definition", "offset": [52, 70]}, {"key": "approval-of", "type": "definition", "offset": [116, 127]}, {"key": "drug-product", "type": "definition", "offset": [132, 144]}], "snippet": "means the pre-clinical studies, clinical trials and regulatory filings and related steps directed toward Regulatory Approval of the Drug Product.", "size": 3, "samples": [{"hash": "bKbVNe5kW6S", "uri": "/contracts/bKbVNe5kW6S#clinical-development-program", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "7zco0EfkoBW", "uri": "/contracts/7zco0EfkoBW#clinical-development-program", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "5LMGgLA0F2E", "uri": "/contracts/5LMGgLA0F2E#clinical-development-program", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "0b0e41be6c0dd776f89e3a489eac569d", "id": 4}, {"snippet_links": [{"key": "development-program-activities", "type": "clause", "offset": [15, 45]}, {"key": "as-amended", "type": "definition", "offset": [113, 123]}, {"key": "from-time-to-time", "type": "clause", "offset": [124, 141]}, {"key": "yearly-updates", "type": "clause", "offset": [152, 166]}], "snippet": "means the drug development program activities of BIOCHEM for the Drug Candidates to be described in SCHEDULE 1.5 as amended from time to time including yearly updates.", "size": 2, "samples": [{"hash": "jU1JlvfHWP4", "uri": "/contracts/jU1JlvfHWP4#clinical-development-program", "label": "Research and License Agreement (Scriptgen Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "3cY0fCrs03A", "uri": "/contracts/3cY0fCrs03A#clinical-development-program", "label": "Research and License Agreement (Scriptgen Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "67a8c583e2986cf5b89474d1e1061343", "id": 5}, {"snippet_links": [{"key": "the-program", "type": "clause", "offset": [6, 17]}], "snippet": "means the program described in Appendix A.", "size": 2, "samples": [{"hash": "k8wD7QgyHGk", "uri": "/contracts/k8wD7QgyHGk#clinical-development-program", "label": "License, Development and Supply Agreement (Imi International Medical Innovations Inc)", "score": 18.0, "published": true}, {"hash": "aiwzTCIYe3z", "uri": "/contracts/aiwzTCIYe3z#clinical-development-program", "label": "License, Development and Supply Agreement (Imi International Medical Innovations Inc)", "score": 18.0, "published": true}], "hash": "557700c524b3a2c38837581d998c9916", "id": 6}, {"snippet_links": [{"key": "conduct-of", "type": "clause", "offset": [10, 20]}, {"key": "development-of-a", "type": "clause", "offset": [30, 46]}, {"key": "pharmaceutical-product", "type": "clause", "offset": [47, 69]}, {"key": "applicable-regulatory-authority", "type": "definition", "offset": [113, 144]}, {"key": "pursuant-to-such", "type": "clause", "offset": [145, 161]}], "snippet": "means the conduct of clinical development of a pharmaceutical product for which an IND has been submitted to the applicable Regulatory Authority pursuant to such IND.", "size": 2, "samples": [{"hash": "livSCX9dgVT", "uri": "/contracts/livSCX9dgVT#clinical-development-program", "label": "Research and Development Collaboration and License Agreement (Zoetis Inc.)", "score": 23.855578371, "published": true}], "hash": "85350dde8eefd25a287d4fb3674198af", "id": 7}, {"snippet_links": [{"key": "section-23", "type": "clause", "offset": [36, 47]}], "snippet": "shall have the meaning set forth in Section 2.3.", "size": 2, "samples": [{"hash": "gRN7dckHx32", "uri": "/contracts/gRN7dckHx32#clinical-development-program", "label": "License and Collaborative Research Agreement (Corixa Corp)", "score": 18.0, "published": true}], "hash": "4e7fc546b4c0b344daf0e660d606119b", "id": 8}, {"snippet_links": [{"key": "the-pre", "type": "clause", "offset": [6, 13]}, {"key": "clinical-studies", "type": "clause", "offset": [14, 30]}], "snippet": "means the pre-clinical studies,", "size": 1, "samples": [{"hash": "7KeujW42PWf", "uri": "https://investors.vrtx.com/static-files/f9be8329-b9a3-4b9e-b1db-38c051731b0f", "label": "investors.vrtx.com", "score": 7.9650924025, "published": false}], "hash": "cab320f4d9f02df4e86d253d25f56199", "id": 9}, {"snippet_links": [{"key": "territory-a", "type": "definition", "offset": [10, 21]}, {"key": "territory-b", "type": "definition", "offset": [59, 70]}], "snippet": "means the Territory A Clinical Development Program and the Territory B Clinical Development Program, collectively.", "size": 1, "samples": [{"hash": "8bxxAW0KnQJ", "uri": "/contracts/8bxxAW0KnQJ#clinical-development-program", "label": "License, Development and Commercialization Agreement (Corixa Corp)", "score": 18.0, "published": true}], "hash": "7fbd2bf2911171e2b02713c0294bedab", "id": 10}], "next_curs": "CmkSY2oVc35sYXdpbnNpZGVyY29udHJhY3RzckULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIlY2xpbmljYWwtZGV2ZWxvcG1lbnQtcHJvZ3JhbSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Clinical Development Program", "snippet": "means the program described in Article IV of this Development Agreement.", "size": 31, "id": "clinical-development-program", "examples": ["The Project Team shall coordinate the efforts of the parties with respect to the <strong>Clinical Development Program</strong>.", "Lilly and Ophidian will disclose and make available to each other promptly the results of the work conducted in the <strong>Clinical Development Program</strong>, Process Development Program and Manufacturing Program, including without limitation all preclinical, clinical, regulatory, and other information known by Lilly or Ophidian concerning the Drug Product at any time during the term of this Agreement.", "Pursuant to an agreement in the form of the Stock Purchase Agreement, if Genentech has decided to proceed with the <strong>Clinical Development Program</strong> after the review under Section 4.05(b), and prior to starting the first Phase II Clinical Trial, if at all, Genentech shall purchase CTI Common Stock in an amount equal to the agreed-upon Phase II Clinical Development Expenses, at a price equal to one hundred percent (100%) of the 20 Day Average of CTI&#x27;s Common Stock.", "At the earlier of the end of the term of the Development Program or the completion of the Initial Clinical Trial, Genentech will decide whether to continue the Development Program, proceed to the <strong>Clinical Development Program</strong>, or terminate the program, all as provided in Section 4.05.", "Upon Genentech&#x27;s decision pursuant to Section 4.05(b) to commence the <strong>Clinical Development Program</strong>, pursuant to Section 8.01(b) Genentech will purchase Common Stock pursuant to an agreement in the form of the Stock Purchase Agreement, in an amount equal to the agreed-upon Phase II Clinical Development Expenses.", "The Project Team shall provide the day-to-day management for the collaboration and shall be responsible for directing and overseeing specific activities hereunder, including but not limited to the <strong>Clinical Development Program</strong>, the Process Development Program and the Manufacturing Program.", "If Genentech decides to continue the <strong>Clinical Development Program</strong> after the review under Section 4.05(c), the Parties shall agree on a budget for U.S. Phase III Clinical Development Expenses.", "Patentable inventions or discoveries which arise from the Research Program or the <strong>Clinical Development Program</strong> [***]*.", "The Parties agree that the &quot;<strong>Clinical Development Program</strong>&quot; includes, among other items, all human clinical studies of Licensed Products directed toward approval of a Submission in the United States (after the Initial Clinical Trial), manufacturing scale-up and other work to develop and commercialize Licensed Products.", "During each <strong>Clinical Development Program</strong>, Angiotech shall direct all <strong>Clinical Development Program</strong> activities after the completion of Phase I Studies."], "related": [["clinical-development", "Clinical Development", "Clinical Development"], ["commercial-development-plan", "Commercial Development Plan", "Commercial Development Plan"], ["development-program", "Development Program", "Development Program"], ["initial-development-plan", "Initial Development Plan", "Initial Development Plan"], ["development-plan", "Development Plan", "Development Plan"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}